Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EYEG
  • CUSIP:
Key Metrics:
  • Previous Close: $2.81
  • 50 Day Moving Average: $1.73
  • 200 Day Moving Average: $1.68
  • 52-Week Range: $1.11 - $5.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.19
  • P/E Growth: 0.00
  • Market Cap: $26.93M
  • Outstanding Shares: 9,585,000
  • Beta: 2.37
Profitability:
  • Return on Equity: -219.82%
  • Return on Assets: -109.13%
Debt:
  • Current Ratio: 1.02%
  • Quick Ratio: 1.02%
Additional Links:
Companies Related to Eyegate Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Eyegate Pharmaceuticals (NASDAQ:EYEG) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.20 (227.40% upside)

Analysts' Ratings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Show:
DateFirmActionRatingPrice TargetDetails
12/6/2016HC WainwrightSet Price TargetBuy$10.00View Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00View Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
6/28/2016Maxim GroupReiterated RatingHoldView Rating Details
4/7/2016Noble FinancialInitiated CoverageBuy -> Buy$10.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
2/23/2017($0.42)N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Insider Ownership Percentage: 26.50%
Institutional Ownership Percentage: 6.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.00View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.00View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.00View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.09View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eyegate Pharmaceuticals (NASDAQ:EYEG)
DateHeadline
News IconTrader Alert: Unusual Volume Spotted in Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Winfield Review (NASDAQ:EYEG)
winfieldreview.com - February 23 at 10:08 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports full-year 2016 financial results - Reuters (NASDAQ:EYEG)
www.reuters.com - February 23 at 10:08 PM
News IconEye-Catching Stock: Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) - Post Registrar (NASDAQ:EYEG)
postregistrar.com - February 23 at 10:08 PM
prnewswire.com logoValeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post ... - PR Newswire (press release) (NASDAQ:EYEG)
www.prnewswire.com - February 23 at 10:08 PM
News IconEyegate Pharmaceuticals Inc (NASDAQ:EYEG) Licensing Deal Assessment And Breakdown (NASDAQ:EYEG)
wallstreetpr.com - February 23 at 5:07 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report (NASDAQ:EYEG)
biz.yahoo.com - February 23 at 5:07 PM
finance.yahoo.com logoEyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update (NASDAQ:EYEG)
finance.yahoo.com - February 23 at 5:07 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing (NASDAQ:EYEG)
www.reuters.com - February 22 at 5:24 PM
4-traders.com logoEyegate Pharmaceuticals Inc : Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS (NASDAQ:EYEG)
www.4-traders.com - February 22 at 5:24 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:EYEG)
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoStock Futures Rise After Walmart, Home Depot Top Earnings Estimates (NASDAQ:EYEG)
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoDow Higher for Eighth Straight Session as Retailers Rise (NASDAQ:EYEG)
us.rd.yahoo.com - February 22 at 5:24 PM
News IconGrowth Analysis of: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - StandardOracle (NASDAQ:EYEG)
standardoracle.com - February 22 at 9:11 AM
News IconWhich insiders are buying Eyegate Pharmaceuticals, Inc. (EYEG)? - Post Analyst (NASDAQ:EYEG)
postanalyst.com - February 22 at 9:11 AM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing - Reuters (NASDAQ:EYEG)
www.reuters.com - February 22 at 9:11 AM
News IconEyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Stock Passes into Potential Pullback Range - Aiken Advocate (NASDAQ:EYEG)
aikenadvocate.com - February 22 at 9:11 AM
News IconBustling Stock in Focus: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Winfield Review (NASDAQ:EYEG)
winfieldreview.com - February 22 at 9:11 AM
nasdaq.com logoMid-Afternoon Market Update: Dow Surges Over 100 Points - Nasdaq - Nasdaq (NASDAQ:EYEG)
www.nasdaq.com - February 22 at 9:11 AM
finance.yahoo.com logoEyeGate Pharmaceuticals Licensing Deal Review and Breakdown (NASDAQ:EYEG)
finance.yahoo.com - February 22 at 9:11 AM
sbwire.com logo"Ocular Inflammation Global Clinical Trials Review, H2, 2016" Published (NASDAQ:EYEG)
www.sbwire.com - February 18 at 7:49 AM
News IconTrading Scope: Checking the Levels for Eyegate Pharmaceuticals Inc. W (EYEGW) - Baxter Review (NASDAQ:EYEG)
baxternewsreview.com - February 16 at 5:04 PM
News IconConsensus Watch on Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Rockville Register (NASDAQ:EYEG)
rockvilleregister.com - February 16 at 5:04 PM
News IconTurbulence Hits These Shares as Volume Spikes: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Aiken Advocate (NASDAQ:EYEG)
aikenadvocate.com - February 16 at 5:04 PM
openpr.com logoWet Macular Degeneration Market Research Report by Geographical Analysis and Forecast to 2024 (NASDAQ:EYEG)
www.openpr.com - February 13 at 5:55 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St (NASDAQ:EYEG)
biz.yahoo.com - February 8 at 5:39 PM
us.rd.yahoo.com logo4:02 pm Eyegate Pharmaceuticals appoints Sarah Romano, Corporate Controller, as interim CFO (NASDAQ:EYEG)
us.rd.yahoo.com - February 7 at 6:18 PM
reuters.com logoBRIEF-EyeGate Pharmaceuticals announces executive promotions (NASDAQ:EYEG)
www.reuters.com - February 7 at 3:11 AM
streetinsider.com logoEyegate Pharma (EYEG) Names Sarah Romano as Interim CFO (NASDAQ:EYEG)
www.streetinsider.com - February 7 at 3:11 AM
finance.yahoo.com logoEyeGate Pharmaceuticals Announces Executive Promotions (NASDAQ:EYEG)
finance.yahoo.com - February 6 at 5:09 PM
News IconOcular bandage gel effective against corneal epithelial defects (NASDAQ:EYEG)
www.healio.com - February 3 at 10:32 PM
News IconSignal Watch: Checking the Numbers for Eyegate Pharmaceuticals Inc. W (EYEGW) - Sherwood Daily (NASDAQ:EYEG)
sherwooddaily.com - February 3 at 5:31 PM
News IconOcular bandage gel effective against corneal epithelial defects - Healio (NASDAQ:EYEG)
www.healio.com - February 3 at 5:31 PM
News IconChart Level Analysis on Shares of Eyegate Pharmaceuticals Inc (EYEG) - Sherwood Daily (NASDAQ:EYEG)
sherwooddaily.com - February 3 at 5:31 PM
finance.yahoo.com logoEYEG: Positive OBG Clinical Data, Larger Study Already Planned (NASDAQ:EYEG)
finance.yahoo.com - February 3 at 5:31 PM
News IconInvesting Focus: Indicators in View on Shares of Eyegate Pharmaceuticals Inc (EYEG) - Sherwood Daily (NASDAQ:EYEG)
sherwooddaily.com - February 2 at 10:42 PM
News IconPlacing the Bulls-Eye Focus on Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Prospect Journal (NASDAQ:EYEG)
prospectjournal.com - January 31 at 10:49 PM
News IconKeen Investors Taking a Look at Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Prospect Journal (NASDAQ:EYEG)
prospectjournal.com - January 31 at 10:49 PM
News IconNoticeable Stock: Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) - Post Registrar (NASDAQ:EYEG)
postregistrar.com - January 31 at 10:49 PM
streetinsider.com logoEyegate Pharma (EYEG) Reports Encouraging EyeGate OBG Top-Line Results from First-in-Human Pilot Trial - StreetInsider.com (NASDAQ:EYEG)
www.streetinsider.com - January 31 at 10:49 PM
4-traders.com logoNetworkNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Shares Higher on Encouraging Top-line Data from Trial of Ocular Bandage Gel (NASDAQ:EYEG)
www.4-traders.com - January 30 at 5:49 PM
247wallst.com logoIs This The Beginning of EyeGate’s Rally? (NASDAQ:EYEG)
247wallst.com - January 30 at 5:26 PM
reuters.com logoBRIEF-Eyegate Pharma announces positive top-line data from first-in-human pilot trial of ocular bandage gel (NASDAQ:EYEG)
www.reuters.com - January 30 at 12:08 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Fitbit, Calithera, Eyegate, Rite Aid (NASDAQ:EYEG)
m.nasdaq.com - January 30 at 12:08 PM
streetinsider.com logoEyegate Pharma (EYEG) Reports Encouraging EyeGate OBG Top-Line Results from First-in-Human Pilot Trial (NASDAQ:EYEG)
www.streetinsider.com - January 30 at 12:08 PM
4-traders.com logoEYEGATE PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:EYEG)
www.4-traders.com - January 30 at 12:08 PM
finance.yahoo.com logoEyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects (NASDAQ:EYEG)
finance.yahoo.com - January 30 at 12:08 PM
finance.yahoo.com logo8:31 am EyeGate Pharma announces 'positive' top-line data from first-in-human pilot trial of ocular bandage gel in corneal epithelial defects (NASDAQ:EYEG)
finance.yahoo.com - January 30 at 12:08 PM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Aiken Advocate (NASDAQ:EYEG)
aikenadvocate.com - January 28 at 10:22 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Nelson Research (NASDAQ:EYEG)
nelsonobserver.com - January 28 at 10:22 PM
openpr.com logoFresh Upward Triggers in Wet Macular Degeneration Market till 2024 (NASDAQ:EYEG)
www.openpr.com - January 27 at 11:49 PM

Social

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Where is Eyegate Pharmaceuticals' stock going? Where will Eyegate Pharmaceuticals' stock price be in 2017?

5 analysts have issued 12-month target prices for Eyegate Pharmaceuticals' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Eyegate Pharmaceuticals' stock price to reach $9.20 in the next twelve months.

When will Eyegate Pharmaceuticals announce their earnings?

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

How do I buy Eyegate Pharmaceuticals stock?

Shares of Eyegate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eyegate Pharmaceuticals stock cost?

One share of Eyegate Pharmaceuticals stock can currently be purchased for approximately $2.81.

Eyegate Pharmaceuticals (NASDAQ:EYEG) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Earnings History Chart

Earnings by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Dividend History Chart

Dividend Payments by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Last Updated on 2/23/2017 by MarketBeat.com Staff